NFE2L2 and breast carcinoma: G6PDH (p = 0.011) and cytoplasmic NRF2 (p = 0.001) in metastatic breast cancers were differentially expressed depending on the metastatic sites, with brain metastases showing higher expression of G6PDH and cytoplasmic NRF2 than the other sites (Figure 1 and Table 3).